This guide provides actionable tips for medical device manufacturers to successfully navigate the FDA premarket cybersecurity submission process, ensuring clearance and avoiding common pitfalls such as rejections, deficiencies, and costly rework. It emphasizes comprehensive preparation and documentation.
Prepare thorough and accurate documentation including SPDF, SBOMs, threat models, and penetration test reports to meet FDA expectations and avoid submission rejections. Incomplete documentation is a primary cause of FDA feedback and delays.
Ensure your cybersecurity submission adheres to established standards and frameworks like ISO 14971, FDA 2026 Guidance, UL 2900, AAMI TIR57/TIR97, NIST 800-115, IEC 62304, IEC 81001-5-1, and ANSI/AAMI SW96. This alignment demonstrates a robust cybersecurity posture.
Systematically identify threats using industry-standard methodologies and conduct deep vulnerability and penetration testing on both the device and its entire ecosystem (cloud/mobile). This proactive approach helps mitigate risks before submission.
When conducting penetration testing, consider not just the device but also its associated cloud infrastructure and mobile applications. Many vendors overlook the broader ecosystem, which can introduce vulnerabilities.
Initiate discussions with cybersecurity experts early in your development process to understand FDA requirements and develop a tailored strategy. Early engagement can prevent delays and costly issues later on.
Include transitive dependencies, not just top-level components. Pin every component to a specific version with a hash and supplier. CycloneDX or SPDX, machine-readable — free-form component lists are being cited as incomplete under the Feb 3, 2026 guidance.
Labeling now must communicate a security-support horizon: how long you commit to shipping security updates and what happens after. Draft the HDO-facing statement early — a missing end-of-support plan is a common labeling deficiency.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
It is the cybersecurity portion of your 510(k), De Novo, or PMA package, addressing the six elements enumerated in Section 524B and detailed in the FDA's February 3 2026 premarket cybersecurity guidance: security risk management, security architecture, security testing, SBOM, vulnerability disclosure/handling, and labeling.
Missing or shallow threat models, no penetration testing evidence, SBOMs without VEX, weak coordinated vulnerability disclosure processes, and cybersecurity claims that are not traceable back to design controls. Refuse-to-Accept decisions almost always cite one of these.
Yes. Section 524B applies to any 'cyber device' regardless of submission pathway. The depth of documentation may scale with device risk class, but the six required elements are the same.
Section 524B of the FD&C Act (added by the 2023 Omnibus) makes cybersecurity a statutory requirement for 'cyber devices.' Sponsors must submit a plan to monitor and address postmarket vulnerabilities, design and maintain the device to be reasonably cybersecure, and provide a Software Bill of Materials.
For a team with an SPDF in place, 4-8 weeks. For a team producing artifacts for the first time, 3-6 months. Threat modeling and independent penetration testing are usually the long-pole items.
Jump to all guides for the lifecycle phase that fits where you are.